BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
6/8 — Strong
Priority Review
ADAKVEO (crizanlizumab) by Novartis is p-selectin blockers [moa]. Approved for selectin blocker [epc]. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADAKVEO (crizanlizumab) is a humanized monoclonal antibody that blocks P-selectin, a cell adhesion molecule implicated in vaso-occlusive crisis pathophysiology. It is approved for sickle cell disease patients to reduce the frequency of vaso-occlusive crises. The drug works by preventing interactions between blood cells and the vascular endothelium, thereby reducing inflammatory adhesion events.
$0.007BPart D
PeakPeak-stage product with modest Part D penetration (~594 claims in 2023) suggests established but niche market positioning; commercial team likely stabilized around core sickle cell franchise.
Mechanism of Action
P-Selectin Blockers
Pharmacologic Class:
Selectin Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Started Oct 2024
315 enrolled
Sickle Cell Disease
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
Started Jul 2024
30 enrolled
Sickle Cell Disease
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
Started Dec 2022
376 enrolled
Sickle Cell Disease
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
Started Aug 2022
31 enrolled
Sickle Cell Disease
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
Started Nov 2021
44 enrolled
Sickle Cell Disease
Worked on ADAKVEO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.